Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) PT at $41.75
Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average – Here’s Why
Head to Head Comparison: Parnell Pharmaceuticals (OTCMKTS:PARNF) and Assembly Biosciences (NASDAQ:ASMB)
Financial Survey: Assembly Biosciences (NASDAQ:ASMB) and Sol-Gel Technologies (NASDAQ:SLGL)
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of “Moderate Buy” by Analysts
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $41.25 Consensus PT from Brokerages
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
Assembly Biosciences Announces Upcoming Investor Conference Participation
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains?
Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?